Abstract: This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.

Abstract: An example distributed system for trip estimation is described. The system includes a plurality of sensors disposed in a plurality of geographically distributed facilities. Each of the plurality of geographically distributed facilities includes departments including retrievable items, and each one of the plurality of geographically distributed facilities includes at least one of the plurality of sensors in each of the departments. The system includes a computing system in communication with the plurality of sensors and the one or more databases. The computing system can be configured to receive an item and a source geographic location from a user device, select a subset of the geographically distributed facilities, establish a contemporaneous density of people at a particular department corresponding to the item received from the user device, and output to a user interface on the user device an estimated first transit value based on the contemporaneous density.

Abstract: Cloud computing utilization measurements associated with a cloud computing instance are received. Metrics based on the cloud computing utilization measurements are calculated. Based on a user configurable resource evaluation criteria, whether a different cloud computing instance among eligible cloud computing resource unit options is a better match than a current cloud computing resource unit handling the cloud computing instance is evaluated. A selected one of the eligible cloud computing resource unit options is indicated as the better match than the current cloud computing resource unit handling the cloud computing instance.

Abstract: The compounds of Formula I, Formula Ia, and Formula Ib are described herein along with their analogs, tautomeric forms, stereoisomers, polymorphs, hydrates, solvates, pharmaceutically acceptable salts, pharmaceutical compositions, metabolites, and prodrugs thereof. These compounds inhibit PRMT5 and are useful as therapeutic or ameliorating agent for diseases that are involved in cellular growth such as malignant tumors, schizophrenia, Alzheimer's disease, Parkinson's disease and the like.

Abstract: The present invention relates to a thin-film composite (TFC) membrane composition comprising macrocycles. The invention also relates in part to a method of fabricating a TFC membrane and to a method of using the TFC membrane to separate a desired liquid or gas from a liquid or gas mixture.

Abstract: Described here are methods and compositions for treating tumors and metastases that improve anti-angiogenesis therapy. By inhibiting these mechanisms in a biological system with an anti-beta one integrin composition in combination with an antiangiogenic composition, tumors and metastases may be deprived of an adequate blood supply, thereby resulting in tumor cell growth arrest and possibly regression, including tumor cell death. The present compositions comprise an anti-beta one integrin agent in combination with an anti-VEGF agent, in a pharmaceutical composition or compositions. Methods of treatment and of imaging are also described.

Abstract: A method for generating a prosodic representation includes receiving a text utterance having one or more words. Each word has at least one syllable having at least one phoneme. The method also includes generating, using a Bidirectional Encoder Representations from Transformers (BERT) model, a sequence of wordpiece embeddings and selecting an utterance embedding for the text utterance, the utterance embedding representing an intended prosody. Each wordpiece embedding is associated with one of the one or more words of the text utterance. For each syllable, using the selected utterance embedding and a prosody model that incorporates the BERT model, the method also includes generating a corresponding prosodic syllable embedding for the syllable based on the wordpiece embedding associated with the word that includes the syllable and predicting a duration of the syllable by encoding linguistic features of each phoneme of the syllable with the corresponding prosodic syllable embedding for the syllable.

Abstract: The present disclosure provides a DNA plasmid comprising a sequence which encodes an mRNA molecule and a modified poly(A) tail, wherein the part of the sequence that encodes the modified poly(A) tail is characterized in that it consists of at least two A elements each defined as a nucleotide sequence consisting of 55 to 65 T nucleotides and at least one S element each S element consisting of one nucleotide that is not a T nucleotide, or 2 to 10 nucleotides, preferably 6 nucleotides, wherein each of the two terminal nucleotides is not a T nucleotide, wherein the number of A elements is one more than the number of S elements, and wherein any two A elements are separated by one S element; said DNA plasmid exhibiting a reduced recombination during amplification in a bacterial host cell compared to the same DNA plasmid without said at least one S element.

Abstract: The present disclosure describes membrane compositions and methods for preparing membrane compositions. In particular, the methods employ a layer-by-layer approach to membrane preparation. The membrane compositions provide significantly enhanced membrane performance over existing commercial membranes, particularly in terms of permeability and selectivity.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: Described is an RNA molecule comprising (a) a coding region coding for a polypeptide; and (b) upstream of said coding region one or more UTR(s) comprising the sequence as shown in SEQ ID NO:1 or a sequence which shows 1 to 4 substitutions in comparison to SEQ ID NO:1 and which results in an RNA molecule having the same or a higher translation efficiency as an RNA molecule comprising an UTR comprising SEQ ID NO:1; and/or (c) downstream of said coding region one or more UTR(s) comprising the sequence as shown in SEQ ID NO:2 or a sequence which shows 1 to 7 substitutions in comparison to SEQ ID NO:2 and which results in an RNA molecule having the same or a higher translation efficiency as an RNA molecule comprising an UTR comprising SEQ ID NO:2; wherein said polypeptide encoded by said coding region is not a cytochrome b-245 alpha polypeptide (CYBA). Moreover, described is a nucleic acid molecule encoding the RNA molecule according to the present invention.

Abstract: Methods and system for solving an issue in an infrastructure is described. The method comprises identifying (201) the issue based on monitoring of the infrastructure, extracting (203) one or more standalone solutions related to the identified issue from a repository, creating (205) one or more combination of solutions from the extracted one or more standalone solutions, computing (207) Multi Directional Truepath Discovery (MDTD) score for each of the extracted one or more solutions and each of the created combination of solutions, selecting (209) either a standalone solution or a combination of solutions based on highest MDTD score, and implementing (211) the selected standalone solution or combination of solutions.

Abstract: The present disclosure relates to identifying azimuth error and determining an azimuth of an antenna installed in a cell of a cellular network. In a preferred embodiment, the network entity receives a plurality of transmission parameters basis to which the network entity identifies a target cell. The network entity further divides angular region of the cell serving the target cell into a plurality of cones out of which a target cone is identified by the network entity. The network entity then performs first iteration yielding a first azimuth, and in an event of an azimuth error in the first azimuth, the network entity performs second iteration yielding a second azimuth. The present disclosure also encompasses predicting an optimum azimuth of said antenna in an event of azimuth error/s in the first azimuth and the second azimuth.

Abstract: An object of the present invention is to provide an isoxazole compound or a salt thereof that controls pests. The present invention provides an isoxazole compound represented by Formula (I): or a salt thereof, wherein R represents C1-6 alkyl, or C1-4 haloalkyl; A1 and A2 are identical or different and each halogen or C1-6 alkyl; B1 represents hydrogen, halogen or C1-6 alkyl; B2 represents C1-6 alkyl, C1-4 haloalkyl, or substituted or unsubstituted aryl C1-4 haloalkyl; and n represents an integer of 0 to 2.

Abstract: In certain aspects, the disclosure relates to compositions comprising modified Ornithine transcarbamylase (OTC) polyribonucleotides and methods of use.

Abstract: Methods and systems herein relate to unmanned aerial vehicles (UAVs) avoiding collisions by interacting with servers. Some embodiments of a method include receiving, by an unmanned aircraft system (UAS) traffic management (UTM) server one or more intended trajectories from one or more UAVs; determining, by the UTM server one or more conflicts based on the intended trajectories intersecting over a region monitored by the UTM server; and communicating, by the UTM server the one or more conflicts, the communicating includes assigning a value to each of a plurality of three-dimensional (3D) grid cells representing the region monitored by the UTM server, each value representative of a potential for conflict associated with a grid cell; and transmitting, to the one or more UAVs, value data associated with the plurality of grid cells.

Abstract: A transition duct support apparatus and a method to support an exit frame in a transition duct in a gas turbine engine are provided. A stiffener (24) may be arranged to provide support to an outer edge (27) of an exit frame (12) in a transition duct (14). Stiffener (24) may be configured to circumferentially extend between mutually opposed corners (30) of the exit frame of the transition duct. A brace (26) may be connected to a centrally-disposed section (20) and may extend to support respective end portions (32) of the stiffener. The support apparatus is effective to provide a respective tuned level of stiffness support with respect to one or more axes of the exit frame in the transition duct. The apparatus and method may be effective for distributing mechanical stresses on the exit frame of the transition duct and/or neighboring regions in the transition duct.

Abstract: The invention provides compositions for forming a hydrophobic or superhydrophobic material, the composition comprising a polyol component having at least two hydroxyl groups per molecule on average; an isocyanate component having at least two isocyanate groups per molecule on average; a single population of nanoparticles having a particle size less than 1 pm; and a solvent; wherein the population of nanoparticles represents at least 5 wt. % of the total of the polyol component, isocyanate component, and population of nanoparticles. The invention also provides hydrophobic or superhydrophobic materials formed from the compositions of the invention, and methods or kits for forming such materials.

Abstract: Disclosed are formulations/compositions comprising a BTK inhibitor, particularly ibrutinib: as well as processes for preparing such formulations/compositions and methods of treatment of a disease or condition that comprises the use of such formulations/compositions.

Abstract: Methods of and systems for removing organic substance from condensate generated from an industrial evaporation process are provided. The condensate comprises water and the organic substance. The methods and systems provide solutions related to enthalpy recovery of industrial evaporation processes such as, for example, sugar cane juice evaporation processes, dairy evaporation processes, coffee processing evaporation processes, fruit juice evaporation processes, soup evaporation processes, and chemical industry evaporation processes.